Animal biotech company Gallant has entered a fulfillment agreement with MWI Animal Health to establish the first-ever ultra-low-temperature (-80\u00b0C) cold-chain distribution network for veterinary practices. The agreement positions clinics nationwide to have safe, reliable access to off-the-shelf stem cell therapies intended for veterinary use, pending FDA approval.<\/p>\n
The partnership lays the logistical groundwork for what could be the first FDA-approved off-the-shelf stem cell therapy for companion animals. Combining Gallant\u2019s regenerative medicine innovations with MWI\u2019s national distribution infrastructure, the companies aim to make advanced biologics more accessible and practical for clinics everywhere.<\/p>\n
According to the agreement, MWI will create and operate a scalable fulfillment model, including ultra-cold-temperature-controlled storage and shipping. Operations will be based out of MWI\u2019s Kansas facility, with overnight shipping across the continental United States, as well as Alaska, Hawaii, and Puerto Rico.<\/p>\n
Sonruvetcel \u2014 Gallant\u2019s potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell (MSC) therapy for cats with refractory chronic gingivostomatitis \u2014 is anticipated to be the first product supported by the ultra-low-temperature cold chain. If conditionally approved by the FDA\u2019s Center for Veterinary Medicine (FDA-CVM), the therapy would be delivered as an off-the-shelf product for in-clinic use.<\/p>\n
\u201cBreakthrough science only matters if we can safely and reliably put it into the hands of veterinary professionals,\u201d said Dr. Linda Black, chief executive officer of Gallant. \u201cWith MWI, we are pairing regenerative medicine innovation with world-class supply chain management. This partnership helps ensure that, once approved, veterinarians can conveniently access an FDA-regulated, off-the-shelf stem cell therapy with confidence in its quality and integrity.\u201d<\/p>\n
This news comes as a survey conducted by the American Animal Hospital Association and Gallant revealed that:<\/p>\n
\u201cThis partnership demonstrates how distribution innovation can unlock clinical innovation,\u201d said Julia Loew, chief commercial officer at MWI Animal Health. \u201cStem cell therapies require precision handling. By investing in ultra-low-temperature logistics tailored to veterinary practice, we are ensuring that this category of innovation can be delivered in the exact state intended, ready for safe and effective use.\u201d<\/p>\n
The infrastructure is ultimately intended to support Gallant\u2019s future therapies targeting inflammatory and degenerative conditions in companion animals.<\/p>\n","protected":false},"excerpt":{"rendered":"
Gallant and MWI to establish an ultra-low-temperature fulfillment model for reliable clinic delivery.<\/p>\n","protected":false},"author":823,"featured_media":79128,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":0,"footnotes":""},"categories":[90],"tags":[],"class_list":["post-79127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-online","column-news","clinical_topics-innovation-technology","clinical_topics-news"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"\n